The present invention concerns amphiphilic copolymers that may be photo- or redox-cleavable and that may assemble into polymersomes. It also concerns their process of preparation and their use as ding carriers.

The present application is directed to a theranostic probe and its use for targeting and/or labeling the EGFR kinase and/or the cells expressing EGFR or its family members.

Progenitor cells were isolated, purified and expanded using a microfluidic based cell sorting approach. The methods were successfully in purifying cone progenitor cells (CPCs) defined based on a proliferative population expressing cone arrestin and Red/Green (R/G) opsin at greater than 80% using a two multistage approach.

The present disclosure relates to genetically modified non-human animals that express a human or chimeric (e.g., humanized) TNFR2, and methods of use thereof.

The disclosure provides a mouse model of arteriovenous malformation, such as found in Hereditary Hemorrhagic Telangiectasia, that accurately and persistently models the disease progression in various organisms, including humans. The disclosure further provides a mouse comprising a mutant Ephrin pathway gene, such as Alk1, in brain endothelial cells only, and methods of screening for therapeutically useful modulators of Ephrin pathway gene expression or gene product activity useful in treating or ameliorating a symptom of arteriovenous malformation, such as Hereditary Hemorrhagic Telangiectasia or hemorrhagic stroke.

Described herein are polymeric compounds including an acceptor dye and donor luminophore, a polymer, and optionally a bioconjugate group. A polymeric compound of the present invention may have a structure represented by: A-B-C or C-A-B, wherein A is an acceptor dye; B is a polymer comprising one or more hydrophobic unit(s) and one or more hydrophilic unit(s); and optionally C, wherein C, when present, comprises a bioconjugate group, wherein one or more donor luminophore(s) are each separately attached to a portion of the polymer and/or to a portion of the acceptor dye. Also described herein are compositions comprising the polymeric compounds and methods of preparing and using the same.

The present invention relates to providing fluorescent silica nanoparticles having high luminance even when many fluorescent dyes are contained in silica particles. Fluorescent silica nanoparticles according to the present invention is fluorescent silica nanoparticles including silica nanoparticles and fluorescent dyes contained in the silica nanoparticles, in which a total volume of the fluorescent dyes is 5% or more with respect to a total volume of the fluorescent silica nanoparticles, and an emission quantum yield of the fluorescent silica nanoparticles is 10% or more.

Methods are described to reduce risk of or prevent wooden chest syndrome or other respiratory effects arising from exposure to fentanyl or a fentanyl analog, for instances inpatients receiving medically assisted treatment (MAT) for Opioid Use Disorder (OUD) or who are receiving analgesia and pain management with F/FAs. Pharmaceutical compositions for use in such methods are described.

Fluorescent bimetallic nanocomposites (M.sub.1@M.sub.2-NCs) of silver-gold (Ag@Au-NC) and silver-platinum (Ag@Pt-NC) are prepared by reducing silver nitrate (AgNO.sub.3) on gold nanoparticles (AuNPs) and platinum nanoparticles (PtNPs) using sodium borohydride (NaBH.sub.4) at alkaline pH=11, in the presence of a lysozyme that acts as a template, and in the presence of a capping and stabilizing agent. The biocompatible bimetallic nanocomposites (M.sub.1@M.sub.2-NCs) have promising multifunctional applications (cell imaging, bio-sensing, therapeutics) observed by both in vitro as well as in vivo experiments. The fluorescent bimetallic nanocomposites (M.sub.1@M.sub.2-NCs) of silver-gold (Ag@Au-NC) and silver-platinum (Ag@Pt-NC) may be useful as an alternative nanomedicine in cancer theranostics applications.

The presently disclosed subject matter provides compositions, kits, and methods comprising imaging agents that can detect Programmed Death Ligand 1 (PD-L1). The presently disclosed imaging agents can be used to detect diseases and disorders, such as cancer, infection, and inflammation, in a subject.